Plain-English translation of NCT06209853 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostatic Neoplasms research guide →Researchers want to understand how a routine blood test called PSA (prostate-specific antigen) relates to the results of a specialized imaging scan called F-18 PSMA PET/CT in men with prostate cancer. This scan uses special imaging technology to detect cancer cells in the body. The study will help doctors understand whether PSA levels can predict how well this imaging scan will find cancer.
Doctors need better ways to know which imaging tests will work best for finding prostate cancer, especially when it returns after treatment. Understanding the connection between PSA blood levels and imaging results could help guide treatment decisions and improve how doctors monitor patients.
You would undergo an F-18 PSMA PET/CT scan at the hospital's nuclear medicine department—a specialized imaging procedure that takes pictures to detect cancer cells. Researchers will compare your blood PSA levels with your scan results to see if there is a relationship. The study does not involve taking any new medication; it simply observes how your existing PSA test results relate to the imaging findings.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Egypt
Enrollment target
~59 participants
Started
January 2024
Primary completion
March 2025
Sex
Male only
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Aalaa W Hussein, master
Assiut University